A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism

Keyphrases

• Novel Class 100%
• Cyclin-dependent Kinase Inhibitor 100%
• Cdks 100%
• Molecular Docking 100%
• Unique Mechanism 100%
• Cyclin-dependent Kinase 2 (CDK2) 40%
• High-throughput 20%
• Therapeutic Target 20%
• Protein Aggregation 20%
• Small Molecules 20%
• Cancer Treatment 20%
• Mechanism of Action 20%
• Cyclin-dependent Kinase 4 (CDK4) 20%
• Drug-induced 20%
• Protein Level 20%
• Cyclin-dependent Kinase 20%
• Control Process 20%
• Cyclin-dependent Kinase 1 (CDK1) 20%
• Cytostatic Effect 20%
• Cell Cycle Arrest 20%
• Kinase Family 20%
• ATP-competitive 20%
• Decreased Expression 20%
• In Silico Screening 20%
• Multiple Lines of Evidence 20%
• CDK7 20%
• Rb Phosphorylation 20%
• Cyclin-dependent Kinase 9 (CDK9) 20%
• Direct Induction 20%

Biochemistry, Genetics and Molecular Biology

• Cell Cycle 100%
• Docking (Molecular) 100%
• Cyclin-Dependent Kinase 100%
• Small Molecule 25%
• Transcription 25%
• Protein Aggregation 25%
• E2F 25%
• Cell Cycle Arrest 25%
• Cell Cycle Checkpoint 25%
• Adenosine Triphosphate 25%
• Cyclin-Dependent Kinase 2 25%
• Cyclin-Dependent Kinase 4 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cyclin Dependent Kinase Inhibitor 100%
• Cyclin Dependent Kinase 2 50%
• Malignant Neoplasm 50%
• Cyclin Dependent Kinase 4 50%
• Cyclin Dependent Kinase 50%
• Cytostatic Agent 50%
• Adenosine Triphosphate 50%